CD1a immunopositivity could help to address prognosis of intestinal-type Barrett's metaplasia Sir: I read with great interest the letter of Lopes et al. that compared Alcian blue-periodic acid-Schiff stain with immunohistochemistry for MUC-2 in 40 patients with Barrett's metaplasia (BM) of intestinal-type (IT).
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In their research, they found that 'MUC-2 expression turned out to be a helpful tool for the correct identification of intestinal metaplasia, avoiding any false-negative of even false-positive results'.
We agree with them that 'an adequate diagnosis' of BM 'is very important' for the management of this disease, but since 'the incidence of adenocarcinoma in this epithelium ranges between 0.2% and 2.1% in patients without dysplasia and up to 70% in those with high-grade dysplasia', we consider of greater interest to have a test that may help to predict the prognosis.
As the anti-tumoral role of CD1a was recently postulated, we investigated its presence in metaplastic epithelium of Barrett's oesophagus, both gastric and IT. CD1a is a surface glycoprotein of 49 kDa commonly expressed by dendritic cells, cortical thymocytes and Langerhans cells of skin and mucosa; moreover, immunoexpression of CD1a is commonly researched to differentiate various cutaneous lymphomas (T-cell) from B-cell lymphomas and pseudolymphomas.
In a preliminary work on 113 biopsies of BM, we reported that the most of cases (75%) of BM were positive for CD1a; 2 in particular, we were the first to demonstrate that CD1a could be expressed by epithelial cells, other that dendritic cells, in BM. Consequently, we reported that the expression of CD1a by metaplastic epithelial cells might help to distinguish BM by the presence of heterotopic mucosa in the esophageal wall.
Recently, we examined 65 patients with IT BM and we found that 55 of them were positive for CD1a ( Figure 1A) , while normal intestinal mucosa is always negative ( Figure 1B) . Nevertheless, eight of 10 patients that were negative for CD1a underwent dysplasia at 1-3 years follow-up. Dysplastic tissues were also negative for CD1a ( Figure 1C) . By contrast, IT BM diagnosis was confirmed at follow-up of all 55 positive cases.
Our data already suggested that this marker might help to predict the prognosis of this pathology in both gastric-and IT BM. 2 In light of our recent experiments, we feel it necessary to confirm this hypothesis.
In conclusion, although malignant transformation may be a rare event, we suggest that CD1a could be a new marker not only to distinguish heterotopic mucosa from BM but also to predict the prognosis of this condition.
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